A voluntary agreement between the Government and the pharmaceutical industry.
The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues including medicines regulation, UK and EU trading relationships, access to talent, and the future of UK science.
The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines.
The Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have welcomed the publication of "Continuity in the availability of goods for the EU and the UK", published today by the UK Government's Department for Exiting the European Union.
As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.
ABPI Member webinar
The chance to hear a monthly update on the work and arrangements on Brexit and the implications for our business.
Friday 02 November 201812:00 - 13:00
The webinar will be hosted by Elliot Dunster, Head of External Affairs who will be joined by colleagues on specific issues as they arise.
Please note, this webinar is for ABPI member company colleagues only. Please ensure you register with your company email address in order to gain access.